EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients

Dan P Zandberg iD, Serafettin Zenkin, Murat Ak, Priyadarshini Mamindla, Vishal Peddagangireddy, Ronan Hsieh, Jennifer L Anderson, Greg M Delgoffe, Ashely Menk, Heath D Skinner, Umamaheswar Duvvuri, Robert L Ferris und 1 weitere

Head & Neck · 2025

DOI: 10.1002/hed.27878 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von Dan P Zandberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH/NCI SPORE in Head and Neck Cancer, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti‐PD‐1 mAb (IO) in R/M HNSCC.

Methods

Radiomic feature extraction was performed on pre‐treatment CT scans segmented using 3D slicer v4.10.2 and key features were selected using LASSO regularization method to build classification models with XGBoost algorithm by incorporating cross‐validation techniques to calculate accuracy, sensitivity, and specificity. Outcome measures evaluated were disease control rate (DCR) by RECIST 1.1, PFS, and OS and hypoxia and CD8 T cells in the TME.

Results

Radiomics features predicted DCR with accuracy, sensitivity, and specificity of 76%, 73%, and 83%, for OS 77%, 86%, 70%, PFS 82%, 75%, 89%, and in the TME, for high hypoxia 80%, 88%, and 72% and high CD8 T cells 91%, 83%, and 100%, respectively.

Conclusion

Radiomics accurately predicted the efficacy of IO and features of the TME in R/M HNSCC. Further study in a larger patient population is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsNeoplasm Recurrence, LocalHumansRetrospective StudiesMaleFemaleMiddle AgedAgedTomography, X-Ray ComputedTreatment OutcomeAdultImmune Checkpoint InhibitorsPredictive Value of TestsProgrammed Cell Death 1 ReceptorRadiomics

Stichwörter der Autor:innen

artificial intelligencehead and neck squamous cell carcinomaimagingimmunotherapymachine learningpembrolizumabradiomicstreatment response

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Dan P Zandberg

Förderung

  • NIH/NCI SPORE in Head and Neck Cancer
  • NCI NIH HHS
  • NIAID NIH HHS
  • NIDCR NIH HHS
  • The University of Pittsburgh Hillman Cancer Center startup funding (RRC)
  • University of Pittsburgh Hillman Cancer Center NCI Cancer Center Support Grant (CCSG) (RRC)

Zitieren

APA

Zandberg, D. P., Zenkin, S., Ak, M., Mamindla, P., Peddagangireddy, V., Hsieh, R., Anderson, J. L., Delgoffe, G. M., Menk, A., Skinner, H. D., Duvvuri, U., Ferris, R. L., & Colen, R. R. (2025). Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients. Head & Neck. https://doi.org/10.1002/hed.27878

Vancouver

Zandberg DP, Zenkin S, Ak M, Mamindla P, Peddagangireddy V, Hsieh R, et al. Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients. Head & Neck. 2025. doi:10.1002/hed.27878

BibTeX
@article{Zandberg2025,
  author = {Zandberg, Dan P and Zenkin, Serafettin and Ak, Murat and Mamindla, Priyadarshini and Peddagangireddy, Vishal and Hsieh, Ronan and Anderson, Jennifer L and Delgoffe, Greg M and Menk, Ashely and Skinner, Heath D and Duvvuri, Umamaheswar and Ferris, Robert L and Colen, Rivka R},
  title = {Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐ PD ‐1 mAb treated recurrent/metastatic squamous cell carcinoma of the head and neck patients},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27878}
}
Kostenlos starten →